The Centers for Medicare & Medicaid Services yesterday approved Louisiana’s Medicaid plan amendment allowing supplemental rebate agreement negotiations with prescription drug makers for Hepatitis C therapies. The new “modified subscription” model allows the state to cap gross expenditures for the Hepatitis C prescriptions for Medicaid and requires manufacturers to provide the drug’s lowest price negotiated in all states in the Medicaid program. “The high cost of prescription drugs is one of the greatest challenges in our health care system,” said CMS Administrator Seema Verma, “and Louisiana’s innovative approach to leveraging a subscription model to promote access to hepatitis C therapy is a great example of how states can lead in designing solutions.” The amendment goes into effect July 1. CMS has approved similar state plan amendments for Washington, Oklahoma, Michigan and Colorado. This is the second one to focus on Hepatitis C.

Related News Articles

Headline
A bipartisan House letter by Reps. Dan Crenshaw, R-Texas, Yvette D. Clarke, D-N.Y., Gus M. Bilirakis, R-Fla., and Diana DeGette, D-Colo., urged House…
Headline
The AHA detailed its key health care priorities for the remainder of the year in comments to House and Senate majority and minority leaders Sept. 15. The AHA…
Headline
The Centers for Medicare & Medicaid Services Sept. 9 issued preliminary guidance regarding the implementation of certain state-directed payment provisions…
Headline
The White House Sept. 9 released its “Make Our Children Healthy Again” strategy report, created to address childhood chronic diseases. The report highlights…
Headline
The AHA and other national hospital organizations Sept. 5 urged Senate and House leadership to act on preventing Medicaid Disproportionate Share Hospital…
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…